Our Team at CPHI Barcelona 2023
-
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
-
Kalpesh Kumar Modi
Vice President and Region Head - Europe
-
Sumit Kumar
Vice President and Region Head - US
-
Gunjan Singh
Vice President and Head- US & Europe
-
Nirav K Shah
Vice President and Head - North Asia
-
B Vivek
Executive VP and Global Head Supply, Demand Planning and Delivery
-
Gustavo Mayrink
Vice President, Sales & Marketing – LATAM
-
Karun Gaur
Vice President - SEMEA
-
Dr. A Kalyan Chakravarthy
Vice President & Head
-
Siddhartha Deshpande
Associate Vice president - SEMEA
-
Rohan Kaushik
Associate Vice President, BD & Portfolio - North Asia
-
Dr. Rajeev Rehani Budhdev
Executive Vice President , API R&D
-
E Sreedhar
Executive VP, API Regulatory Affairs
About CPHI Barcelona 2023

CPHI Barcelona 2023 is an exceptional event at the heart of the pharmaceutical industry, dedicated to advancing human health and fostering global collaboration. Taking place in Barcelona, Spain, this in-person gathering will be held from October 24th to 26th, 2023, at the prestigious Fira Barcelona Gran Via.
At CPHI Barcelona, you'll have the opportunity to collaborate, expand your expertise, and get inspiration from emerginginnovations. We have the perfect pass for you and we can't wait to see you in Barcelona! Schedule your meeting with our team today!
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.

Our Achievement


Renuncia
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.